Table 1.
Recent data on risk factors of hepatocholangiocarcinoma.
| Author | Country | Numbers of patients | Advanced fibrosis | HCV | HBV | Alcohol | Metabolic syndrome |
|---|---|---|---|---|---|---|---|
| Sasaki et al. 201727 | Japan | 53 | 14/24 (58%) | 9/19 (47%) | 9/44 (21%) | 2/19 (11%) | 3/19 (16%) |
| Zhou et al. 2017153 | China | 144 | 91/144 (63.2%) | – | 101/144 (70%) | 29/144 (20%) | – |
| Xue et al. 201929 | China | 121 | 54/115 (47%) | 2/115 (2%) | 89/115 (77%) | – | – |
| Okumura et al. 2020154 | Japan | 89 | 30/89 (34%) | 29/89 (33%) | 37/89 (43%) | – | – |
| Gentile et al. 201919 | Systematic Review | 437 | 226/437 (52%) | 39/437 (9%) | 264/437 (60%) | – | – |
| Wells et al. 201522 | USA | 39 | 12/39 (31%) | 9/39 (23%) | 0/39 | 3/39(8%) | 2/39 (5%) |
| Gigante et al. 201923 | France | 20 | 10/20 (50%) | 1/20 (4%) | 3/20 (15%) | 8/20 (40%) | 6/20 (30%) |
| De Martin 2020∗55 | France | 31 | 31/31 (100%)∗ | – | – | 40/75 (53%) | – |
| Holzner 202054 | USA | 47 | 20/47 (43%) | 15/47 (32%) | 22/47 (47%) | – | – |
We included recent studies with histologically confirmed (Goodman transitional type (type II)/Allen and Lisa type B or C/WHO classical type tumours and stem cell type with exception of CLC, studies already included in the systematic review (Gentile et al. 2019) are not shown.
∗
Study including only lesions on cirrhosis. Data about risk factor prevalence are relatives to the entire cohort of cHCC-CCA and iCCA.